| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.054 | 0.4 |
| mRNA | Obatoclax Mesylate | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | sitagliptin | CTRPv2 | pan-cancer | AAC | 0.068 | 0.4 |
| mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.5 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.033 | 0.5 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.04 | 0.5 |
| mRNA | AS601245 | GDSC1000 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | PF-3758309 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.5 |